LGALS1 and Patent ductus arteriosus: Of note, when genetically inhibiting Gal-1, tumors show a significantly enhanced number of T-cell infiltrates and neutrophils [79], suggesting that galectin-1 may be key in driving immune evasion in PDA [80,81].